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Background: Cholangiocarcinoma (CC) is a fatal malignancy, the incidence of which is increasing
worldwide, with substantial regional variation. Current diagnostic techniques to distinguish benign from
malignant biliary disease are unsatisfactory. Metabolic profiling of bile may help to differentiate benign
from malignant disease. No previous studies have compared the metabolic profiles of bile from two
geographically and racially distinct groups of CC patients.
Objectives: This study aimed to compare metabolic profiles of bile, using in vitro proton magnetic
resonance spectroscopy, from CC patients from Egypt and the UK, and from patients with CC and
patients with non-malignant biliary disease.
Methods: A total of 29 bile samples, collected at cholangiography, were analysed using an 11.7-T
system. Samples were from eight CC patients in either Egypt (n = 4) or the UK (n = 4) and 21 patients with
benign biliary disease (choledocholithiasis [n = 8], sphincter of Oddi dysfunction [n = 8], primary sclerosing
cholangitis [n = 5]).
Results: Bile phosphatidylcholine (PtC) was significantly reduced in CC patients. Egyptian CC patients
had significantly lower biliary PtC levels compared with UK patients. Taurine- and glycine-conjugated bile
acids (H-26 and H-25 protons, respectively) were significantly elevated in bile from patients with CC
compared with bile from patients with benign diseases (P = 0.013 and P < 0.01, respectively).
Conclusions: Biliary PtC levels potentially differentiate CC from benign biliary disease. Reduced biliary
PtC in Egyptian compared with UK patients may reflect underlying carcinogenic mechanisms.
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Introduction
Cholangiocarcinoma (CC) is the second most common primary
hepatic tumour worldwide and its incidence rates have risen
steeply around the world over the past 30 years.1–7 Cholangiocar-
cinoma is usually fatal as a result of its late presentation, the
difficulty of diagnosis and lack of a curative therapy other than
surgical resection. Its diagnosis is challenging as there are no sen-
sitive and specific biomarkers and imaging cannot accurately dif-
ferentiate benign from malignant biliary disease. Most cases
present too late for resection and, consequently, CC has a poor
prognosis.1,2 Most known risk factors for CC are associated with
chronic inflammation of the biliary tree.2,7,8 Primary sclerosing
cholangitis (PSC) is the most common known predisposing con-
dition for CC in Western nations.9 In parts of the world where CC
is most common, such as in Thailand, the malignancy has been
linked to chronic infestation of the biliary tree with liver flukes.
However, most patients do not exhibit any known risk factors and
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there are no known markers of risk for the development of biliary
malignancy. Rates of CC vary greatly among different areas of
the world, possibly reflecting the distribution of risk factors and
their interaction with host genetic differences that may increase
risk for carcinogenesis.2,7,8 We postulate that an imbalance of
lipids and toxic bile acids in bile may have a pathogenic role in
cholangiocarcinogenesis.
Magnetic resonance spectroscopy (MRS) allows the study of
metabolite changes in biofluids and tissues. We, and others, have
previously reported that in vitro MRS of bile may be able
to differentiate between benign and malignant biliary tract
disease.9–11 We have also shown that bile acid levels are signifi-
cantly higher, and phosphatidylcholine (PtC) levels significantly
reduced, in bile from UK CC patients compared with bile from
UK patients with benign biliary disease.10 There are no published
studies to date investigating the metabolic profiles of bile from
Egyptian CC patients, or comparing the bile profiles of two
racially distinct patient groups. Using in vitro MRS, the objectives
of this study were to:
1 compare the metabolic profiles of bile from CC patients from
Egypt and the UK;
2 compare the metabolic profiles of bile from CC patients and
bile from patients with non-malignant biliary disease, and
3 identify potential biomarkers of CC.
Materials and methods
Patients
Sample collection was organized by authors MSHA and MMEC,
following relevant local ethics committee approval. Bile samples
from 29 patients were acquired at endoscopic retrograde cholan-
giopancreatography (ERCP). Eight patients had CC. Four of these
were Egyptian and underwent ERCP at the National Liver Insti-
tute, Egypt, carried out by GAB. The other four patients were from
the UK; their bile samples were collected at Hammersmith Hos-
pital, Imperial College London by AVT and DSB. The diagnosis of
CC was confirmed by a combination of cholangiography, cross-
sectional imaging, elevated tumour markers (CA19-9, CA-125)
and positive histology and/or cytology. Of the Egyptian CC
patients, three had stage II disease (local invasion) and one had
stage III disease (involving regional lymph nodes). Their body
mass indices (BMIs) ranged from 23 to 26. All four of the UK
patients with CC had stage II disease and BMIs of 24–27. A total of
21 patients had non-malignant biliary disease, including choledo-
cholithiasis (n = 8), sphincter of Oddi dysfunction (SOD, n = 8),
and PSC (n = 5). They were diagnosed by AVT and AWS. Three
patients in the control group were Egyptian. They were diagnosed
with choledocholithiasis (n = 2) and PSC (n = 1). Table 1 describes
the patient demographics. Patients in the non-malignant disease
group had BMIs in the range of 22–28. Patients in the choledo-
cholithiasis subgroup had BMIs in the range of 26–28. None of the
patients had cholangitis at the time of bile collection, as evidenced
by clinical assessment and negative cultures. None of the patients
had diabetes.
Bile collection and storage
Approximately 4 ml of bile were obtained at ERCP, after cannula-
tion of the common bile duct and before contrast injection. Bile
samples were stored in the dark at -20 °C prior to MRS analysis.
Sample preparation for bile MRS study
A sample of 600 ml of bile was transferred to a 17.5-cm, 5-mm
diameter nuclear magnetic resonance (NMR) tube containing a
4-mm diameter ‘insert’ tube containing 50 ml of an external
reference standard (15 ml of phosphate buffer 0.2 M/35 ml
sodium trimethylsilyl-propionate [TSP] in deuterium oxide
[D2O] solution).9
Magnetic resonance spectroscopy
Magnetic resonance spectroscopy experiments were performed
using a JEOL 500-MHz NMR spectrometer (JEOL Ltd, Tokyo,
Japan) and a 11.7 Tesla superconducting magnet (Oxford Instru-
ments, Plc, Oxford, UK). The 1H NMR spectra were obtained
using a pulse–collect sequence (pulse angle, 90 °; repetition
time, 22 s; relaxation delay, 20 s; number of scans, 32) in com-
bination with a pre-saturation technique and Hahn spin-echo
sequencing.
Spectral interpretation
Bile spectra were analysed using the KnowItAll Informatics
System, Version 7.9 (Bio-Rad Laboratories, Philadelphia, PA,
USA). Peaks were referenced to the chemical shift of TSP at
0.0 ppm. Spectra were autophased and subsequently manually
phased after the removal of the water peak (4.5–5.2 ppm), using
Table 1 Demographic and clinicopathological characteristics of patients enrolled in the study
Disease Cholangiocarcinoma Choleodocholithiasis SOD PSC
Patients, n 8 8 8 5
Age, years, mean (range) 68 (56–82) 59 (33–79) 50 (27–62) 39 (28–66)
Sex
Male, n 5 0 0 5
Female, n 3 8 8 0
SOD, sphincter of Oddi dysfunction; PSC, primary sclerosing cholangitis
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the software flat-line function. A baseline correction was applied
using the spline algorithm. Peaks were assigned according to
established databases and previously published literature.12,13 For
relative quantification, peak areas were manually integrated and
expressed as a percentage ratio to the total spectral signal (range:
10–0.2 ppm).
Statistical analysis
Statistical analysis was performed using spss for Windows Version
14.0 (SPSS, Inc., Chicago, IL, USA). Because of the small sample
sizes of the groups, no assumptions of normality were made and
non-parametric tests (Kruskal–Wallis and Mann–Whitney
U-tests) were used to compare disease groups.
Results
Phosphatidylcholine concentration was reduced in bile from CC
patients compared with bile from patients with benign biliary
diseases. The median value of the PtC proton resonance at
1.2 ppm (tail group) was significantly lower in CC bile compared
Table 2 Summary of the results of spectral integral values of major metabolites in bile
All CC
patients
(n = 8)
Egyptian CC
patients
(n = 4)
UK CC
patients
(n = 4)
SOD
patients
(n = 8)
Choledocholithiasis
patients (n = 8)
PSC
patients
(n = 5)
H-25 taurine-conjugated bile acids 1.2 0.8 1.6 0.6 0.6 0.4
(0.3–2.1) (0.6–1.5) (0.3–2.0) (1.2–1.5) (0.1–1.3) (0.1–0.9)
H-26 taurine-conjugated bile acids 0.9 1.6 0.9 0.6 0.5 0.5
(0.6–2.5) (0.6–2.5) (0.8–1.3) (0.5–0.8) (0.1–2.8) (0.3–0.7)
H-25 glycine-conjugated bile acids 1.3 1.5 1.3 0.7 0.8 0.6
(0.8–3.5) (0.8–3.5) (1–1.6) (0.5–0.9) (0.2–1.5) (0.4–0.7)
PtC tail group 24.0 19.4 24.9 26.5 28.2 29.5
(CH2)2 (9.5–26.3) (9.5–24.9) (22.7–26.3) (24.8–27.1) (11.4–34.6) (13.5–30.0)
PtC head group 4.0 4.2 3.9 3.8 4.5 4.8
N-(CH3)3 (3.1–11.0) (3.2–11.0) (3.1–4.3) (3.4–4.4) (2.3–6.0) (2.4–5.2)
PtC 2.7 2.8 2.7 3.2 2.6 3.4
b-CH2 (1.6–4.9) (1.6–4.9) (2.1–3.5) (2.0–3.7) (2.1–3.5) (1.8–3.7)
PtC 1.0 0.8 1.4 0.6 0.7 0.94
a-CH2 (0.5–1.3) (0.2–1.1) (1.2–1.5) (0.4–1.1) (0.2–1.2) (0.6–1.5)
Values are presented as medians and interquartile ranges
CC, cholangiocarcinoma; SOD, sphincter of Oddi dysfunction; PSC, primary sclerosing cholangitis; PtC, phosphatidylcholine
Table 3 Comparison between the different groups for spectral integral values of bile acids metabolites, phosphatidylcholine, choline,
lactate and cholesterol metabolites in bile
CC vs. all
groups
Egyptian vs. UK
CC patients
CC vs.
SOD
CC vs.
choledcholithiasis
CC vs.
PSC
H-18 bile acids <0.01 0.15 <0.01 0.14 0.057
H-21 bile acids 0.78 0.77 0.46 0.46 0.30
H-25 taurine-conjugated bile acids 0.15 0.25 0.11 0.09 0.057
H-26 taurine-conjugated bile acids 0.013 1.0 0.012 0.059 <0.01
H-25 glycine-conjugated bile acids <0.01 0.056 <0.01 0.059 <0.01
Total conjugated bile acids 0.96 0.30 0.79 0.53 0.76
PtC tail group (CH2)2 0.06 0.15 <0.01 0.74 0.10
PtC head group
N-(CH3)3
0.09 0.38 0.53 0.09 0.38
PtC, b-CH2 0.39 1.0 0.40 0.83 0.46
PtC, a-CH2 0.25 0.02 0.09 0.21 0.60
Choline, a-CH2 0.76 0.15 0.40 0.46 0.46
Values depicted in bold are significant at P < 0.05
CC, cholangiocarcinoma; SOD, sphincter of Oddi dysfunction; PSC, primary sclerosing cholangitis; PtC, phosphatidylcholine
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with SOD bile (P < 0.01). In addition, PtC resonance at 4.3 ppm
(a-CH2) was significantly lower in bile from Egyptian CC
patients than in bile from UK CC patients (P = 0.02). Taurine-
conjugated (H-26 proton) and glycine-conjugated (H-25 proton)
bile acids were significantly elevated in bile from patients with CC
compared with bile from patients with benign biliary diseases (P =
0.013 and P < 0.01, respectively). This difference was significantly
higher in CC bile compared with bile from SOD (P = 0.012
and P < 0.01, respectively) and PSC (P < 0.01 and P < 0.01,
respectively) patients. Tables 2 and 3 show the median values,
interquartile ranges and P-values for comparisons of the major
biliary metabolites. Figures 1 and 2 compare bile acids and PtC
between the groups.
Discussion
Cholangiocarcinoma incidence rates are increasing worldwide,
with substantial regional variation. Current diagnostic techniques
to distinguish benign from malignant biliary tract disease are
unsatisfactory, but the metabolic profiling of bile may differentiate
benign from malignant biliary disease. This is the first study to
compare the metabolic profiles of bile from CC patients from two
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Figure 1 Distribution of (A) H-25 glycine-conjugated bile acid and (B) H-26 taurine-conjugated bile acid amongst the study
groups. *Cholangiocarcinoma vs. benign biliary disease, P < 0.05. SOD, sphincter of Oddi dysfunction; PSC, primary sclerosing
cholangitis
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geographically and racially distinct groups. We found that bile PtC
is significantly reduced and taurine-conjugated (H-26) and
glycine-conjugated (H-25) bile acids are significantly elevated in
bile from patients with CC, compared with bile from patients with
benign diseases.
Theoretically, several factors may have impacted our results.
The bile lipid profile can be affected by the individual’s metabolic
condition and weight. None of the patients had diabetes and,
although patient BMIs were marginally higher in the benign
disease group, particularly in those with choledocholithiasis, the
overall difference was small. Recent dietary habits can also affect
the bile metabonome, albeit in an unpredictable manner. All
patients were fasted for8 h prior to the collection of bile. Recent
weight loss may also potentially affect the biliary lipid profile.
Most patients in both groups reported having lost weight in the 3
months prior to bile collection at ERCP, but the amount of weight
lost was not verifiable in most cases and thus any potential impact
on our data is unclear.
We have confirmed our previous findings of significantly higher
bile acid levels and significantly lower PtC levels in bile from CC
patients compared with bile from patients with benign biliary
disease.9,10 Further, we have established that these findings are not
confined to White UK patients, but also occur in another distinct
racial group comprising Egyptian patients. Phosphatidylcholine is
the major phospholipid in mammalian cells and is essential
for membrane structure, signal transduction and lipoprotein
metabolism.14 It is synthesized in the hepatocyte endoplasmic
reticulum from choline and subsequently transported into the
biliary canaliculus by the flippase multidrug-resistant protein 3
(MDR3).15 Its main function in bile is to form mixed micelles with
bile acids and cholesterol, essential for the emulsification of fats.
Phosphatidylcholine has also been shown to have a cytoprotective
role in the biliary epithelium and may reduce the cellular toxicity
of bile acids.16,17 Peak integrals for tail group PtC assignments were
lower in bile from CC patients than in bile from patients with
other biliary diseases. However, this difference did not reach sta-
tistical significance except with SOD.
We also found that PtC peak assignment, at 4.3 (a-CH2),was
significantly lower in Egyptian than UK patients with CC. The
reduction in biliary PtC observed from our proton MR results
may be potentially explained by impaired transport of PtC.
Genetic variations in biliary transporter proteins, such as MDR3,
would lead to reduced phospholipid export and a subsequent
reduction in biliary PtC. This would disrupt micellar formation,
leading to the formation of bile acid monomers which are more
toxic to the cholangiocyte cell membrane, cause inflammation
and, in theory, can induce carcinogenesis.18,19 Studies have shown
that mdr2 knockout mice (the mice analogue of MDR3) produce
bile with high bile acids and low PtC content. These mice develop
both hepatocellular carcinoma and CC.20 The finding of reduced
PtC in Egyptian patients with CC is consistent with the hypothesis
that underlying biliary transporter differences exist in these
patients.
Another significant finding of this study is that the peak integral
values of both glycine- and taurine-conjugated bile acids were
significantly higher in CC bile compared with bile from disease
controls. The greatest difference was seen when comparing CC
bile with bile from the SOD and PSC patient groups. We propose
that bile acids may play a role in the pathogenesis of CC. Bile acids
cause oxidative DNA damage, induce frequent apoptosis and, after
repeated exposure, select for cells resistant to apoptosis, which
leads to DNA mutation and carcinogenesis.19–21 Bile acids may also
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Figure 2 Distribution of phosphatidylcholine (PtC) tail group amongst the various biliary diseases. Cholangiocarcinoma vs. all groups,
P = 0.06; cholangiocarcinoma vs. SOD, P < 0.05. SOD, sphincter of Oddi dysfunction; PSC, primary sclerosing cholangitis
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promote direct cholangiocyte growth by activating the epidermal
growth factor receptor and, via the mitogen-activated protein
kinase signalling pathway, leading to disordered cell cycling and
cholangiocyte proliferation.22,23 Thus, elevated conjugated bile
acids in CC bile may play an aetiopathogenic role and the relative
ratio of conjugated bile acids and phospholipids may also serve as
a potential biomarker of the disease. In conclusion, this early study
addresses the feasibility of using MRS to assess metabolite changes
in bile for diagnostic purposes and to provide insights into the
pathogenesis of CC. Magnetic resonance spectroscopy of bile may
have a future role in delineating biomarker panels for the diagno-
sis of CC and may potentially inform the direction of future
genetic studies on disease susceptibility in different populations.
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